Patents by Inventor Masayoshi Matsuo

Masayoshi Matsuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11926018
    Abstract: There is provided an apparatus for polishing, comprising a polishing table configured to support and rotate a polishing pad; a holder configured to hold an object and press the object against the polishing pad; a polishing solution supply device provided with a contact member and configured to supply a polishing solution to an opening in a bottom face of the contact member in a state that the contact member comes into contact with or is adjacent to the polishing pad, thereby spreading the polishing solution on the polishing pad, the polishing solution supply device causing at least part of used polishing solution returned by rotation of the polishing pad to be dammed up by the contact member and setting the contact member either in a direction of keeping the dammed up polishing solution on the polishing pad or in a direction of discharging the dammed up polishing solution, according to an angle of the polishing solution supply device with respect to a radial direction of the polishing pad; an arm linked with
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 12, 2024
    Assignee: EBARA CORPORATION
    Inventors: Masayoshi Ito, Hisanori Matsuo, Itsuki Kobata, Takuya Moriura
  • Patent number: 9783609
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 10, 2017
    Assignees: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20150118234
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Applicants: TASUKU HONJO, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
  • Patent number: 8951518
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 10, 2015
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20130164294
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 27, 2013
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 8246955
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: August 21, 2012
    Assignees: Ono Pharmaceutical Co., Ltd., Tasuku Honjo
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20110280878
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: June 27, 2011
    Publication date: November 17, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
  • Patent number: 7998479
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 16, 2011
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 7858746
    Abstract: Compounds that can recognize selectively both PD-1 protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1. The compounds are useful for medical treatment and/or prevention of diseases caused by immune abnormality.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 28, 2010
    Assignees: ONO Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Masayoshi Matsuo, Takao Yoshida
  • Publication number: 20090263865
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: May 20, 2009
    Publication date: October 22, 2009
    Applicants: Tasuku HONJO, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 7563869
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: July 21, 2009
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20090076250
    Abstract: Compounds that can recognize selectively both PD-1 protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1. The compounds are useful for medical treatment and/or prevention of diseases caused by immune abnormality.
    Type: Application
    Filed: March 28, 2008
    Publication date: March 19, 2009
    Inventors: Tasuku HONJO, Shiro Shibayama, Masayoshi Matsuo, Takao Yoshida
  • Publication number: 20080025979
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: January 22, 2004
    Publication date: January 31, 2008
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20050267114
    Abstract: Compounds represented by formula (I) (wherein all of the symbols have the same meanings as defined in specification.), quaternary ammonium salts thereof, N-oxides thereof or salts thereof. The compounds represented by formula (I) are used for prevention and/or treatment of various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, chronic rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis and the like), immunologic diseases (autoimmune diseases, transplant rejection, immunosuppression, psoriasis, multiple sclerosis and the like), human immunodeficiency virus (acquired immunodeficiency syndrome and the like), allergic diseases (atopic dermatitis, nettle rash, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis and the like), ischemia-reperfusion injury, acute respiratory distress syndrome, shock accompanied by bacterial infection, diabetes mellitus, or metastasis and the like.
    Type: Application
    Filed: September 17, 2003
    Publication date: December 1, 2005
    Inventors: Yoshikazu Takaoka, Rena Nishizawa, Shiro Shibayama, Kenji Sagawa, Masayoshi Matsuo
  • Publication number: 20040241745
    Abstract: Substances comprising a substance that recognizes PD-1, a substance that recognizes a membrane protein co-existing with PD-1 on a cell membrane, and a linker.
    Type: Application
    Filed: February 2, 2004
    Publication date: December 2, 2004
    Inventors: Tasuku Honjo, Shiro Shibayama, Masayoshi Matsuo, Takao Yoshida
  • Patent number: 6441131
    Abstract: A peptide of the formula (I) (wherein each symbol is as defined in the description.) or an acid addition salt thereof. A compound of the formula (I) is a specific substrate for human pepsin II, so it can be used for assaying human pepsin II or human pepsinogen II and it is useful for diagnosis of gastric diseases such as gastric cancer and gastric ulcer.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: August 27, 2002
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Akio Hayashi, Masayoshi Matsuo
  • Publication number: 20020099019
    Abstract: Peptides of the formula (I)
    Type: Application
    Filed: November 15, 2001
    Publication date: July 25, 2002
    Inventors: Akio Hayashi, Masayoshi Matsuo
  • Patent number: 6407206
    Abstract: Peptide substrates, or acid addition salts thereof, wherein said peptide substrate is represented by formula (I): R-X-Pro-Ile-Glu-W-Y-Z  (I) wherein R is a hydrogen, an amino-protective group, or a residue carrying one or two D- or L-amino acids; X is Lys or Arg; W is Phe or Phe(NO2), wherein Phe(NO2) is p-nitrophenylalanine; Y is Phe, Phe(NO2), Tyr, 3,5-diiodotyrosine, norleucine, Leu, Asp(Osbzl) or Met, wherein Obzl is benzyloxy; and Z is an aniline, an aminocoumarin or an aminonapthalene derivative, are disclosed. These compounds are specific substrates for human pepsin I and are useful in assaying the presence of human pepsin I or human pepsinogen I, and useful in diagnosing gastric diseases, such as gastric cancer and gastric ulcer.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: June 18, 2002
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Akio Hayashi, Masayoshi Matsuo
  • Patent number: 4629043
    Abstract: An improved electric parking brake system for a vehicle capable of controlling the brake-applying and releasing operations of a parking brake in an optimal manner in accordance with the gradient of the road on which the vehicle is stopped.
    Type: Grant
    Filed: January 31, 1984
    Date of Patent: December 16, 1986
    Assignee: Mazda Motor Corporation
    Inventors: Masayoshi Matsuo, Kazuhiro Takagishi, Kouji Tobita, Yukihiro Kanemaru
  • Patent number: 4125399
    Abstract: Apex seal for rotary piston engines made of an iron-based material containing in weight 2.5 to 4.0% of C, 0.5 to 2.8% of Si, less than 1.0% of Mn, 0.25 to 2.0% of Ni, 0.25 to 2.0% of Mo, 0.25 to 2.0% of Cu, 0.15 to 0.4% of B, 0.15 to 1.5% of Cr, 0.1 - 0.4% of V and the balance of substantially iron. The material is of a chilled structure which is produced when the material is casted without any specific cooling. The apex seal provides remarkably improved wear and impact resistant properties.
    Type: Grant
    Filed: August 26, 1977
    Date of Patent: November 14, 1978
    Assignee: Toyo Kogyo Co., Ltd.
    Inventors: Fumio Kizu, Kazuyoshi Hanano, Kaoru Sotoyama, Masayoshi Matsuo